DUXAP10 and hepatocellular carcinoma: Interestingly, DUXAP10, the potential HCC diagnostic biomarker in HCC blood exosomes, was also overexpressed in HCC samples with poor prognosis (FDR < 0.05), suggesting that the expression of this lncRNA in exosome may be used to predict patient’s prognosis with validation from further clinical studies.